Elite in Pulmonary Fibrosis

Christopher S. King

Holistic Medicine
15 Center St # 1, 
Ardsley, NY 
Elite in Pulmonary Fibrosis
15 Center St # 1, 
Ardsley, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher King is a Holistic Medicine provider in Ardsley, New York. Mr. King is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Fibrosis, Venous Thromboembolism (VTE), Gallbladder Disease, Endoscopy, and Embolectomy.

His clinical research consists of co-authoring 135 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 29 articles and participated in 3 clinical trials in the study of Pulmonary Fibrosis.

Specialties
Holistic Medicine
Licenses
Acupuncturist in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

15 Center St # 1, Ardsley, NY 10502
Other Locations
302-1 Fremont Street, Peekskill, NY 10566

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
Pulmonary Fibrosis Foundation Patient Registry
Pulmonary Fibrosis Foundation Patient Registry
Enrollment Status: Completed
Publish Date: July 07, 2023
A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support
A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support
Enrollment Status: Terminated
Publish Date: October 14, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)
Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

135 Total Publications

ACR Appropriateness Criteria® Management of Acute Pulmonary Embolism.
ACR Appropriateness Criteria® Management of Acute Pulmonary Embolism.
Journal: Journal of the American College of Radiology : JACR
Published: August 22, 2025
Similar Doctors
Advanced in Pulmonary Fibrosis
Dr. Sang H. Lee
Holistic Medicine
Advanced in Pulmonary Fibrosis
Dr. Sang H. Lee
Holistic Medicine
38w 32nd Street, Floor 10, 
Manhattan New York City, NY 
 (19.8 miles away)
214-714-1004
Languages Spoken:
English

Sang Lee is a Holistic Medicine provider in Manhattan New York City, New York. Mr. Lee is rated as an Advanced provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Fibrosis, Gallbladder Disease, Fractured Spine, Percutaneous Coronary Intervention (PCI), and Stent Placement.

Advanced in Pulmonary Fibrosis
Yan J. Xu
Holistic Medicine
Advanced in Pulmonary Fibrosis
Yan J. Xu
Holistic Medicine
325 Reef Rd, Suite 110, 
Fairfield, CT 
 (31.8 miles away)
203-256-8999
Languages Spoken:
English

Yan Xu is a Holistic Medicine provider in Fairfield, Connecticut. Ms. Xu is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Periodontitis, Venous Thromboembolism (VTE), Liver Failure, Endoscopy, and Hepato-Pancreato-Biliary Surgery.

Advanced in Pulmonary Fibrosis
Ying H. Li
Holistic Medicine
Advanced in Pulmonary Fibrosis
Ying H. Li
Holistic Medicine
236 Crystal Run Rd, Suite 2, 
Middletown, NY 
 (40.4 miles away)
845-294-4350
Languages Spoken:
English

Ying Li is a Holistic Medicine provider in Middletown, New York. Ms. Li is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Liver Failure, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Lung Nodules, Osteotomy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. King's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile